J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frye, R.
Right arrow Articles by Branch, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frye, R.
Right arrow Articles by Branch, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure

RF Frye, A Adedoyin, K Mauro, GR Matzke, and RA Branch

Chlorzoxazone is being developed and proposed for use as a probe to measure in vivo cytochrome P4502E1 activity, but the phenotypic trait measures that are used vary. Although the doses proposed for phenotyping range from 250 mg to 750 mg, the effect of dose on chlorzoxazone hydroxylation has not previously been evaluated. The purpose of this study was to characterize the pharmacokinetics of chlorzoxazone in normal healthy volunteers (N = 6) after single randomized oral doses of 250 mg and 750 mg. An additional 10 volunteers underwent a detailed pharmacokinetic study using the 250-mg dose to further evaluate proposed phenotypic trait measures (N = 16). Timed blood and urine samples were obtained for 10 hours for chlorzoxazone and 6-hydroxychlorzoxazone determination by HPLC. Pharmacokinetic parameter estimates were estimated using noncompartmental methods. Evaluation of phenotypic trait measures show that 6-hydroxychlorzoxazone to chlorzoxazone plasma concentration ratios at 2 to 4 hours after drug administration demonstrated the highest correlations with metabolite formation clearance (r = 0.9; P < 0.001). Urine-based parameters (e.g., total recovery) were not significantly related to formation clearance (r = 0.5; P > 0.05). Dose dependency in chlorzoxazone metabolism was shown by a 30% increase (P < 0.05) in the dose-normalized area under the concentration-time curve (AUC) of chlorzoxazone and lower incremental dose-normalized urinary recovery of 6-hydroxychlorzoxazone at early timepoints after the 750-mg dose. In addition, the plasma ratio of 6-hydroxychlorzoxazone to chlorzoxazone at 4 hours was reduced by 48% in 5 of 6 subjects after the 750-mg dose (P > 0.05). These data suggest that 6-hydroxylation was saturated at the higher dose and illustrate the importance of dose selection in phenotyping. The results of this study indicate that a chlorzoxazone dose of 250 mg should be used and that a single plasma ratio obtained 2 to 4 hours after dosing is reflective of chlorzoxazone 6-hydroxylation and thus may serve as a cytochrome P4502E1 phenotypic trait measure.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
O. Doroshyenko, U. Fuhr, D. Kunz, D. Frank, M. Kinzig, A. Jetter, Y. Reith, A. Lazar, D. Taubert, J. Kirchheiner, et al.
In vivo Role of Cytochrome P450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans
Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 433 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
T. L. Leavens, B. C. Blount, D. M. DeMarini, M. C. Madden, J. L. Valentine, M. W. Case, L. K. Silva, S. H. Warren, N. M. Hanley, and R. A. Pegram
Disposition of Bromodichloromethane in Humans Following Oral and Dermal Exposure
Toxicol. Sci., October 1, 2007; 99(2): 432 - 445.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. B. O'Connell, R. F. Frye, G. R. Matzke, J. V. St. Peter, L. A. Willhite, M. R. Welch, P. Kowal, and J. LaValleur
Effect of Conjugated Equine Estrogens on Oxidative Metabolism in Middle-aged and Elderly Postmenopausal Women.
J. Clin. Pharmacol., November 1, 2006; 46(11): 1299 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. M. Lee, J. Yue, and R. F. Tyndale
In Vivo and in Vitro Characterization of Chlorzoxazone Metabolism and Hepatic CYP2E1 Levels in African Green Monkeys: Induction by Chronic Nicotine Treatment
Drug Metab. Dispos., September 1, 2006; 34(9): 1508 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Zhou, Z. Tong, and J. F. McLeod
"Cocktail" Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science?
J. Clin. Pharmacol., February 1, 2004; 44(2): 120 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
I. Dupont, P. Bodenez, F. Berthou, B. Simon, L. G. Bardou, and D. Lucas
CYTOCHROME P-450 2E1 ACTIVITY AND OXIDATIVE STRESS IN ALCOHOLIC PATIENTS
Alcohol Alcohol., January 1, 2000; 35(1): 98 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. L. Marchand, G. R. Wilkinson, and L. R. Wilkens
Genetic and Dietary Predictors of CYP2E1 Activity: A Phenotyping Study in Hawaii Japanese Using Chlorzoxazone
Cancer Epidemiol. Biomarkers Prev., June 1, 1999; 8(6): 495 - 500.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Clinical Pharmacology